Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate

Graziella Filippini

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish
Pages (from-to)215-216
Number of pages2
JournalEvidence-Based Medicine
Volume22
Issue number6
DOIs
Publication statusPublished - Dec 1 2017

ASJC Scopus subject areas

  • Medicine(all)

Cite this